Press Room

7 March 2022

Targeted Protein Degradation (TPD) by proteasomal PROTACs & molecular glues, lysosomal LYTACs and autophagic AUTOTACs or ATTECs provides plenty of opportunities to drug undruggable targets

BARCELONA, Spain I March 07, 2022 I La Merie Publishing released today its newest report entitled “Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing”. This report describes…

Read more

6 October 2021

Prodrug antibodies and cytokines generated by masking technologies provide plenty of opportunities for founders, investors and partnerships

BARCELONA, Spain I October 06, 2021 I La Merie Publishing announced the release of its newest report about antibody and cytokine prodrugs . The report “Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and…

Read more

1 July 2021

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: an emerging new technology

BARCELONA, Spain I July 1, 2021 I La Merie Publishing announced the release of its newest report about in vivo delivery of nucleic acid-encoded antibodies . The report “Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape…

Read more

11 June 2019

New report about bispecific antibodies engaging T-cells and NK cells

Business, stakeholder, technology and pipeline anaysis STUTTGART, Germany I June 07, 2019 I La Merie Publishing announces the release of a new report entitled „T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis“. Sample pages…

Read more

23 May 2018

TCR Engineered T-Cells 2018: coming out of the shadow to the light

The next two years will give definitive clues about the prospects of this promising treatment modality for solid tumors STUTTGART, Germany I May 23, 2018 I T-Cell Receptors (TCR) and Chimeric Antigen Receptors (CAR) are the cutting edge of adoptive…

Read more

12 March 2018

All time high of biologics sales in 2017 driven by cancer antibodies and innovative anti-inflammatory antibodies

STUTTGART, Germany I March 12, 2017 I Global sales of branded recombinant therapeutic antibodies and proteins in the calendar year 2017 reached an all time high of more than US$ 188 bln, as reported by La Merie Publishing. The increase…

Read more

25 January 2018

Druggability of intracellular targets: a challenging, but highly rewarded goal for emerging technologies to generate TCR fusion proteins, TCRL antibodies and cell-permeating biologics

STUTTGART, Germany I January 25, 2018 I A tissue-based map of the human proteome suggests that about 75 % are intracellular or secreted targets not accessible for conventional monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy (Uhlen et al.,…

Read more

23 June 2017

mRNA Vaccines and Therapeutics: are you ready to be on the ground floor of the next big new therapeutic modality?

STUTTGART, Germany I June 23, 2017 I Overlooked for many years, RNA languished as the ugly stepchild of nucleic acid vaccine development and was thought to be a poor choice for a therapeutic agent given its short half-life in vivo…

Read more

17 March 2017

2016 was another record year of biologics sales with antibodies accounting for two-thirds

STUTTGART, Germany I March 17, 2017 I Sales of branded originator biologics in 2016 continued to reach a record high of US$ 163 bln, a plus of 5.8% compared with the previous year. Growth drivers were therapeutic antibodies for treatment…

Read more

25 January 2017

Oncolytic Viruses: a still undervalued technology with strong growth perspectives

STUTTGART, Germany I January 25, 2017 I The acquisition of oncolytic virus company BioVex by Amgen in late 2011 for up to US$ 1 bln has been a game changer for the field of oncolytic viruses, now recognized as a…

Read more

19 December 2016

More than ever antibody-drug conjugates generated by new technologies are undergoing clinical proof-of-concept testing

STUTTGART, Germany I December 19, 2016 I Since La Merie Publishing released its last Competitor Analysis report about antibody-drug conjugates in April 2013, the number of ADCs in active clinical development has doubled from 33 in 2013 to 65 at…

Read more

9 December 2016

Complimentary copy of report „Blockbuster Biologics 2015: Sales of Recombinant Therapeutic Antibodies & Proteins“

STUTTGART, Germany I December 9, 2016 I As a thank you to the visitors of our website and online readers of press releases posted on, La Merie Publishing offers a complimentary copy of the report „Blockbuster Biologics 2015: Sales…

Read more